|Bid||162.63 x 800|
|Ask||163.06 x 800|
|Day's range||161.16 - 166.00|
|52-week range||117.08 - 312.96|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||3.77|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 June 2022|
|1y target est||N/A|
BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?